Starting studies right can ensure a stronger finish: Oracle A leader from the clinical trial technology firm suggests ways to design research from the start to help accelerate studies and avoid stumbling blocks.
While clinical trials have made a number of advancements in decentralized design, data processing, and other aspects, one area remains a pervasive challenge: startup time. Outsourcing-Pharma recently spoke with Jae Chung, vice president of product management and strategy with Oracle Health Sciences, about solutions to optimize the process, and to increase overall chances of success.
OSP: Why is shortening the timeline of a study desirable? What are some of the forces contributing to the pressure to shorten the study cycle, end to end?
Press release content from Business Wire. The AP news staff was not involved in its creation.
iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego)
February 9, 2021 GMT
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for its proprietary imaging platform iBiopsy® validation. The study is related to the iBiopsy® NASH Clinical Development Plan (CDP).
It is estimated that NASH is affecting 1.5-6.45 % of the global population 1.
(1)
The research collaboration agreement covers a joint clinical retrospective study on liver fibrosis severity in Non-Alcoholic Steato-Hepatitis (NASH) patients
The collaboration will enable Median to work on a large NASH patient cohort to lead the validation of its iBiopsy s AI technology, applied to liver fibrosis characterization
The Liver Center at UC San Diego is a world-renowned university and healthcare center for liver diseases, with a focus on Non-Alcoholic Fatty Liver Disease (NAFLD) NASH
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces today the company has signed a research collaboration agreement with the University of California San Diego (UC San Diego) aimed at carrying out a study that will be used for its proprietary imaging platform iBiopsy validation. The study is related to the iBiopsy NASH Clinical Development Plan (CDP).
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
January 08, 2021 06:00 ET | Source: Chimerix, Inc. Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma
Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million
Management to Host Conference Call at 8:30 a.m. ET Today
DURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce c